Denali Therapeutics Inc (DNLI) — Financial Flexibility Index
Denali Therapeutics Inc (DNLI) has a Financial Flexibility Index of -0.82x as of September 2025. Free cash flow of $-105.92 Million (operating CF $-107.30 Million minus capex $1.38 Million) represents -1% of total liabilities ($129.42 Million). Also explore how fast is Denali Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Denali Therapeutics Inc Financial Flexibility Index (2015–2024)
Historical Financial Flexibility Index trend for Denali Therapeutics Inc across 10 annual periods. Check DNLI capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Denali Therapeutics Inc (2015–2024)
Year-by-year free cash flow to debt coverage for Denali Therapeutics Inc. For the full company profile including market capitalisation, see Denali Therapeutics Inc (DNLI) total market value.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -2.30x | $-331.78 Million | $-347.69 Million | $144.50 Million | ▲ +18.2% |
| 2023 | -2.81x | $-345.05 Million | $-357.99 Million | $122.96 Million | ▼ -416.8% |
| 2022 | -0.54x | $-226.88 Million | $-244.72 Million | $417.81 Million | ▼ -18.3% |
| 2021 | -0.46x | $-202.89 Million | $-211.39 Million | $441.87 Million | ▼ -149.7% |
| 2020 | 0.92x | $419.25 Million | $416.15 Million | $453.75 Million | ▲ +209.5% |
| 2019 | -0.84x | $-133.66 Million | $-151.58 Million | $158.34 Million | ▼ -281.6% |
| 2018 | 0.46x | $53.51 Million | $50.12 Million | $115.14 Million | ▲ +113.2% |
| 2017 | -3.52x | $-73.76 Million | $-76.64 Million | $20.93 Million | ▲ +11.9% |
| 2016 | -4.00x | $-66.22 Million | $-72.36 Million | $16.55 Million | ▼ -1646.2% |
| 2015 | -0.23x | $-11.99 Million | $-15.05 Million | $52.32 Million | — |